Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising
- The company’s shares will remain paused until the earlier of September 23 or when the announcement is made
- On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase 1 clinical study of its RECCE 327 antibiotic
- REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria
- This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327
- Shares in Recce last traded for $1.64 on September 18
Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising.
The company’s shares will remain in a trading halt until the earlier of September 23, or when the announcement is made.
On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase one clinical study of its RECCE 327 antibiotic.
REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria.
This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327.
Recce last entered a trading halt in early September pending the release of anti-viral testing results.
A day later the company announced it had received positive results from early studies of two compounds being tested against the SARS-CoV-2 virus.
This study tested the R327 and R529 drugs against the COVID-19 virus and results showed that both showed increasing efficacy as the doses increased.
Based on these results Recce has been advised it should advance research of both drugs.
Shares in Recce last traded for $1.64 on September 18.
